Besides interfering with IFN, the immune defects associated with diabetes mellitus can prevent the production of interleukin-22 (IL-22), which reduces chronic inflammation, eliciting antimicrobial immunity, maintaining the integrity of the intestinal mucosal barrier, and enhancing insulin sensitivity [41,42,43]. This evidence concerns the gene IFNA1 and diabetes mellitus.